Semiautomatic assessment of whole-body tumor burden with 18F-PSMA-1007 in biochemical recurrent prostate cancer

David R. Cardoza-Ochoa, Cesar Cristancho-Rojas, David J. Pérez, Paola Moreno-Izaguirre, Melissa Guzman, María C. Gutiérrez-Rivera, Aarón P. Gaxiola-Mascareño, Miguel A. Avila-Rodríguez, Belén Rivera-Bravo

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Objective The aim of the study was to evaluate the 18F-PSMA-1007 PET/computed tomography (CT) semiautomatic volumetric parameters to assess the whole-body tumor burden and its correlation with prostate-specific antigen (PSA) and Gleason score in patients with biochemically recurrent prostate cancer (PCa). Materials and methods A total of 110 patients referred for 18F-PSMA-1007 PET/CT due to biochemical recurrence were retrospectively analyzed. Whole-body total lesion prostate-specific membrane antigen (wbTl-PSMA) and whole-body PSMA-derived tumor volume (wbPSMA-TV) metrics on 18F-PSMA-1007 were obtained semiautomatically in dedicated software. A Spearman test was performed to explore the correlation of volumetric imaging parameters with PSA levels and Gleason score. To analyze the association between volumetric measures and PSA subgroups, we used a Kruskal-Wallis test and a Dunn's test to identify each group causing an observed difference. Results A total of 492 metastatic lesions were analyzed, and a significant correlation was found between wbTL-PSMA (R = 0.63, P < 0.0001) and wbPSMA-TV (R = 0.49, P < 0.0001) with serum PSA. A statistically significant difference with wbTL-PSMA was found in patients with a PSA less than or equal 0.5 ng/ml and PSA in the range of 0.51-1.0 ng/ml. Conclusion 18F-PSMA-1007 PSMA volumetric parameters can provide a quantitative imaging biomarker for whole-body tumor burden.

Original languageEnglish (US)
Pages (from-to)332-339
Number of pages8
JournalNuclear Medicine Communications
Volume43
Issue number3
DOIs
StatePublished - Mar 1 2022
Externally publishedYes

Keywords

  • F-PSMA-1007
  • PET-computed tomography
  • PROMISE
  • prostate cancer
  • PSMA-TV
  • TL-PSMA

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint

Dive into the research topics of 'Semiautomatic assessment of whole-body tumor burden with 18F-PSMA-1007 in biochemical recurrent prostate cancer'. Together they form a unique fingerprint.

Cite this